Nomura Holdings
VRDN icon

Nomura Holdings’s Viridian Therapeutics VRDN Stock Holding History

Nomura Holdings’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,205
Closed -$358K – 2071
2026
Q1 		$434K Buy
+22,205
New +$659K ﹤0.01% 1403
2016
Q1 		– Sell
-72
Closed -$12K – 2030
2015
Q4 		$12K Buy
+72
New +$13.9K ﹤0.01% 1810

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nomura Holdings's VRDN Position: Q2 2026 in Review

Nomura Holdings sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 22,205 shares — an estimated $358K sold.

Nomura Holdings first reported a position in VRDN in Q4 2015 and held it in 2 quarters. The position peaked at $434K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Nomura Holdings reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nomura Holdings sold 22,205 Viridian Therapeutics shares in Q2 2026, an estimated $358K.
  • Nomura Holdings first reported a position in Viridian Therapeutics in Q4 2015 and held it in 2 quarters.
  • Nomura Holdings's Viridian Therapeutics position peaked at $434K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.